Literature DB >> 20061427

Serum insulin-like growth factor-binding protein-2 levels and metabolic and cardiovascular risk factors in young adults and children born small for gestational age.

Sandra W K de Kort1, Jaap van Doorn, Ad G M van de Sande, Ralph W J Leunissen, Anita C S Hokken-Koelega.   

Abstract

BACKGROUND: IGF binding protein (IGFBP)-2 might protect against cardiovascular disease. Small for gestational age (SGA) birth could be associated with a higher risk for type 2 diabetes mellitus and cardiovascular disease in later life. No data are available on the relationship between serum IGFBP-2 levels and cardiovascular risk factors in young adults and children born SGA.
OBJECTIVE: The aim of the study was to determine circulating IGFBP-2 levels in subjects born SGA and to investigate the association with cardiovascular risk factors.
METHODS: IGFBP-2 levels were measured in sera from 151 young adults born SGA and 147 short SGA children. Age- and gender-adjusted sd scores (SDS) were calculated. We determined blood pressure, serum lipids, body composition by dual-energy x-ray absorptiometry, and glucose homeostasis by homeostasis model of assessment for insulin resistance or frequently sampled iv glucose tolerance test.
RESULTS: Serum IGFBP-2 SDS was significantly reduced in SGA young adults (with normal or short stature). Fat mass SDS was relatively high in SGA young adults and was reduced in short SGA children. Serum IGFBP-2 SDS in SGA young adults correlated positively with insulin sensitivity and negatively with fat mass SDS, insulin secretion (acute insulin response), fasting insulin, homeostasis model of assessment for insulin resistance, total cholesterol, triglycerides, and blood pressure SDS. The association between serum IGFBP-2 SDS and insulin sensitivity, blood pressure, total cholesterol, and triglyceride levels persisted after adjustment for known covariates including fat mass SDS. In short SGA children, IGFBP-2 SDS did not correlate with any of the cardiovascular risk factors.
CONCLUSION: In young adults who were born SGA, serum IGFBP-2 levels associate with cardiovascular risk markers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061427     DOI: 10.1210/jc.2009-1508

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  IGFBP-2 - taking the lead in growth, metabolism and cancer.

Authors:  Steven W Yau; Walid J Azar; Matthew A Sabin; George A Werther; Vincenzo C Russo
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

2.  The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice.

Authors:  Gang Xi; Melissa A Solum; Christine Wai; Laura A Maile; Clifford J Rosen; David R Clemmons
Journal:  Endocrinology       Date:  2013-08-27       Impact factor: 4.736

Review 3.  Current Insights into the Role of the Growth Hormone-Insulin-Like Growth Factor System in Short Children Born Small for Gestational Age.

Authors:  Judith S Renes; Jaap van Doorn; Anita C S Hokken-Koelega
Journal:  Horm Res Paediatr       Date:  2019-09-11       Impact factor: 2.852

4.  Effects of cord serum insulin, IGF-II, IGFBP-2, IL-6 and cortisol concentrations on human birth weight and length: pilot study.

Authors:  Arianna Smerieri; Maddalena Petraroli; Maria Angela Ziveri; Cecilia Volta; Sergio Bernasconi; Maria E Street
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

5.  MicroRNA-351 eases insulin resistance and liver gluconeogenesis via the PI3K/AKT pathway by inhibiting FLOT2 in mice of gestational diabetes mellitus.

Authors:  Shu-Hong Chen; Xiao-Nan Liu; Yan Peng
Journal:  J Cell Mol Med       Date:  2019-07-09       Impact factor: 5.310

6.  IGFBP-1 and IGFBP-2 are associated with a decreased pulse-wave velocity in young, healthy adults.

Authors:  Paul Pettersson-Pablo; Torbjörn K Nilsson; Lars H Breimer; Anita Hurtig-Wennlöf
Journal:  BMC Cardiovasc Disord       Date:  2021-03-11       Impact factor: 2.298

7.  Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice.

Authors:  Anne Kammel; Sophie Saussenthaler; Markus Jähnert; Wenke Jonas; Laura Stirm; Andreas Hoeflich; Harald Staiger; Andreas Fritsche; Hans-Ulrich Häring; Hans-Georg Joost; Annette Schürmann; Robert W Schwenk
Journal:  Hum Mol Genet       Date:  2016-04-28       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.